A blood test conducted in a prehospital setting may rapidly distinguish between ischemic and hemorrhagic stroke, potentially facilitating more rapid, targeted treatment. The test measures the levels ...

PRAGUE, Czech Republic — A 0.4-mg/kg bolus dose of tenecteplase (TNKase, Genentech) was associated with functional outcomes and safety similar to those seen with the standard of care, alteplase ...

Thrombolytic agents, including tenecteplase, are generally used within 4.5 hours after the onset of stroke symptoms. Information on whether tenecteplase confers benefit beyond 4.5 hours is limited. We ...

A blood test that detects GFAP during emergency transport could kick off effective treatment for these patients before they even get to the hospital, potentially reducing their brain damage from ...